Diabetic nephropathy. Type 2 diabetes mellitus with renal complications
Conditions
Interventions
Intervention 1: Intervention group: The intervention group includes Diabetic patients in whom microalbuminuria has been confirmed, despite standard treatments (Empagliflozin ) , will be undergone o
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
25 Years to 65 Years
Inclusion criteria
Inclusion criteria: Individuals diagnosed with type 2 diabetes between the ages of 25 and 65 are eligible for inclusion in the study. Patients with a Glomerular Filtration Rate (GFR) greater than 25 and less than 90 Absence of liver insufficiency or active liver disease Absence of active infection and sepsis. Exclusion of professional athletes and individuals who have not engaged in intense physical exercise in the 9 days leading up to the sample collection. Patients not currently undergoing treatment with insulin. Patients with no history of polycystic kidney disease. Absence of acute kidney failure due to causes other than diabetes, such as infection. No history of cardiovascular diseases No history of uncontrolled high blood pressure. Absence of cancer or any other endocrine diseases. Not having Glucose 6-phosphate dehydrogenase (G6PD) deficiency
Exclusion criteria
Exclusion criteria: Patient's non-consent for continued cooperation. Absence of cancer or any other endocrine diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in microalbuminuria. Timepoint: At time point zero (prior to drug administration), three months, and six months after drug administration. Method of measurement: laboratory test.;Enhancement in GFR (Glomerular Filtration Rate). Timepoint: At time point zero (prior to drug administration), one month, three months, and six months after drug administration. Method of measurement: Laboratory test and Calculation of the Glomerular Filtration Rate (GFR). | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in creatinine levels. Timepoint: At time point zero (prior to drug administration), one month, three months, and six months after drug administration. Method of measurement: Laboratory test.;Reduction in blood glucose. Timepoint: At time point zero (prior to drug administration), one month, three months, and six months after drug administration. Method of measurement: Laboratory test.;Reduction in blood pressure. Timepoint: At time point zero (prior to drug administration), one month, three months, and six months after drug administration. Method of measurement: Barometer.;Reduction in HbA1C. Timepoint: At time point zero (prior to drug administration), three months, and six months after drug administration. Method of measurement: laboratory test.;Reduction in the incidence of urinary tract infections. Timepoint: At time point zero (prior to drug administration), one month, three months, and six months after drug administration. Method of measurement: laboratory test.;Decrease in serum levels of NO (its metabolites). Timepoint: At time point zero (prior to drug administration), three months, and six months after drug administration. Method of measurement: ELISA.;Reduction in the levels of inflammatory factors((TNF)-a, (IL)-6, (IL)-1ß. Timepoint: At time point zero (prior to drug administration), three months, and six months after drug administration. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDaryoush Hamidi Alamdari
Mashhad University of Medical Sciences
Outcome results
None listed